UNSPSC 51144118: Amphetamine tartrate

This classification denotes a cns stimulant with the molecular formula C9H13N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30G976P30X. European Medicines Agency schedules amfetamine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00439MIG. Most nations, for tariff and trade purposes, schedule amphetamine tartrate under HS 29214600. As of Q4 2014, AMPHETAMINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51144118 Amphetamine tartrate is a Commodity code that nominally identifies a single pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little direct purchase of the amphetamine compound itself. Instead, the solicitations tagged to this code center on broader pharmaceutical procurement — naloxone (an opioid antagonist used in overdose response), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs. State and local health agencies and purchasing alliances are the primary buyers, including county health departments, state health and human services commissions, and multistate cooperative purchasing vehicles. The scope of work encompasses both individual pharmaceutical products acquired through competitive bidding for specific community health initiatives and large-scale generic pharmaceutical sourcing through cooperative agreements that span multiple state and local entities.

Geographic activity centers on Florida and Texas, with multistate reach through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which explicitly extends to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding for quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities. The tag mismatch — amphetamine tartrate does not appear prominently in any recent opportunity — suggests the code's taxonomy label does not align closely with current state and local pharmaceutical procurement demand, which instead clusters around naloxone, generic multi-source products, and pharmacy benefit management models.